Generalized Anxiety Disorder Clinical Trial
Official title:
A Pragmatic Randomized Controlled Trial of a Group Self-management Support Program Versus Treatment-as-usual for Anxiety Disorders
Verified date | May 2024 |
Source | Université de Sherbrooke |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background. Self-management support is a complementary approach to treatment that aims to educate participants on the nature of anxiety and to improve their strategies to manage symptoms and well-being, thus presenting the potential to enhance recovery, improve outcomes, reduce recurrence rates and lower health care costs. There is limited evidence to support the effectiveness of group self-management support for anxiety disorders in community-based care. Objectives. This study aims at examining the effectiveness of a virtual group self-management support program (SMS) for anxiety disorders as an add-on to treatment-as-usual (TAU) in community-based care settings. We will also assess the incremental cost/effectiveness ratio and the implementability of the intervention. Methods. The trial is a pragmatic randomized controlled trial with a pre-treatment, post-treatment (4-month post-randomization), and follow-ups at 8, 12 and 24-months. Intervention. The experimental condition will consist of a 10-week SMS program for anxiety disorders in addition to TAU. The control condition will receive TAU without restrictions for anxiety disorders. Inclusion criteria will comprise being 18 years old or older, French-speaking, and presenting symptoms of anxiety disorders based on self-reported validated assessment scales. Patients will be recruited in the province of Quebec (Canada). Outcome measures: The primary outcome measure is the Beck Anxiety Inventory (BAI). The secondary outcome measures include self-reported instruments for anxiety and depressive symptoms, recovery, self-management, quality of life, and service utilisation. Statistical analysis: Intention-to-treat analysis. A mixed effects regression model will be used to account for between and within-subject variations in the analysis of the longitudinal effects of the intervention. Expected outcomes. The rigorous evaluation of the SMS intervention in the real world will provide information to decision makers, health care managers, clinicians and patients regarding the added value of group SMS for patients with anxiety disorders. Widespread implementation of this intervention could lead to more efficient mental health care services, to better long-term outcomes and to a significant reduction in the extensive social and economic burden of anxiety disorders.
Status | Active, not recruiting |
Enrollment | 414 |
Est. completion date | December 21, 2026 |
Est. primary completion date | March 16, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - (1) aged 18 and over, - (2) fluent in spoken and written French, - (3) presence of symptoms of anxiety disorders based on self-reported validated assessment scales and semi-structured assessment interview, - (4) access to a computer or tablet connected to the internet with microphone and video camera Exclusion Criteria: - (1) previous enrolment in the SMS intervention provided by Relief - (2) active suicidal intentions, - (3) severe depressive symptoms, - (4) active substance-related and addictive disorder, - (5) cognitive impairment |
Country | Name | City | State |
---|---|---|---|
Canada | Université de Sherbrooke | Sherbrooke | Quebec |
Lead Sponsor | Collaborator |
---|---|
Université de Sherbrooke | Canadian Institutes of Health Research (CIHR), Relief |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Gross Cohesion Scale | During the 10-week SMS program, after sessions 3 and 8 (for experimental arm participants) | ||
Other | Working Alliance Inventory | During the 10-week SMS program, after sessions 3 and 8 (for experimental arm participants) | ||
Primary | Change in Beck Anxiety Inventory (BAI) | Baseline and post-treatment (4-month post-randomization) | ||
Secondary | Change in Beck Anxiety Inventory | Baseline, post-treatment, and 8-month, 12-month, 24-month post-randomization follow-ups | ||
Secondary | Change in Generalised Anxiety Disorder-7 | Baseline, post-treatment, and 8-month, 12-month, 24-month post-randomization follow-ups | ||
Secondary | Change in Patient Health Questionnaire-9 | Baseline, post-treatment,12-month and 24-month post-randomization follow-ups | ||
Secondary | Change in Recovery Assessment Scale - Revised | Baseline, post-treatment,12-month and 24-month post-randomization follow-ups | ||
Secondary | Change in Mental Health Self-Management Questionnaire | Baseline, post-treatment,12-month and 24-month post-randomization follow-ups | ||
Secondary | Change in Assessment of Quality of Life - 6 Dimensions | Baseline, post-treatment, and 8-month, 12-month, 24-month post-randomization follow-ups | ||
Secondary | Change in Health care use and indirect costs | Health care costs for other mental health consultations (e.g. type of professional, duration, costs), psychotherapy experience (including CBT) and psychotropic medication. | Baseline, post-treatment, and 8-month, 12-month, 24-month post-randomization follow-ups | |
Secondary | Change in Administrative databases records | Data will be obtained from provincial administrative databases for medical and biopsychosocial services, hospitalization's registry, and medication data. | Starting 12 months prior to participant enrolment up to the 24-month post-randomization follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03420456 -
Transcranial Pulse Near-Infrared Light in Generalized Anxiety Disorder: a Placebo-Controlled Study
|
N/A | |
Active, not recruiting |
NCT05530642 -
An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel
|
N/A | |
Withdrawn |
NCT02382224 -
Worry Exposure for Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT02306356 -
Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting
|
N/A | |
Completed |
NCT02256566 -
Cognitive Training for Mood and Anxiety Disorders
|
N/A | |
Completed |
NCT01958788 -
Testing Beliefs About Uncertainty in the Treatment of Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT01681329 -
Cognitive-Behavioral Treatment and Interpretation Modification Training for Adults With Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT01337713 -
Efficacy of Massage Therapy in the Treatment of Generalized Anxiety Disorder (GAD)
|
N/A | |
Completed |
NCT01201967 -
A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients
|
Phase 4 | |
Completed |
NCT01342120 -
PHARMO Institute Seroquel Safety Study
|
N/A | |
Completed |
NCT01203293 -
Cognitive Behavioral Therapy (CBT) for Latinos With Generalized Anxiety Disorder in the General Medical Sector
|
Phase 1 | |
Completed |
NCT00961298 -
An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder
|
Phase 4 | |
Completed |
NCT01971203 -
Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat
|
N/A | |
Completed |
NCT00744627 -
Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.
|
Phase 3 | |
Completed |
NCT00711737 -
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
|
N/A | |
Terminated |
NCT01244711 -
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
|
Phase 4 | |
Completed |
NCT00537615 -
An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT00525226 -
Evaluating the Effects of Stress in Pregnancy
|
N/A | |
Completed |
NCT00515242 -
Therapeutic Massage for Generalized Anxiety Disorder
|
Phase 1/Phase 2 | |
Completed |
NCT00368745 -
Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.
|
Phase 3 |